Search AI Products and News

Isomorphic Labs, a platform focused on AI-powered drug discovery, founded in 2021 as a spin-off from Google's DeepMind, has secured $600 million in Series A funding led by Thrive Capital, with participation from GV and existing investor Alphabet (Google's parent company). This funding will accelerate the further development of Isomorphic's AI drug design engine and support the company's R&D efforts.

Google recently announced the launch of its new open-source model, TxGemma, designed to significantly improve the efficiency of therapeutic drug development. Developed by the Google DeepMind team, this model is a fine-tuned version of their advanced Gemma model family, incorporating powerful natural language understanding, scientific prediction, and multi-turn dialogue capabilities. TxGemma aims to revolutionize drug discovery. Its release is considered a significant advancement in the application of AI to biomedicine, promising to drastically shorten the time it takes for drugs to move from the lab to clinical trials, while also reducing costs.

Insilico Medicine, a biopharmaceutical company focused on generative artificial intelligence, today announced the successful completion of a $110 million Series E financing round. The round was led by a private equity fund under Value Partners Group (HKG:0806), Pudong New Area Investment, Shanghai Pudong Development Bank Group, Xicheng Capital, and Yixing Guokong. Several new investors focused on the industry and technology sectors also participated, alongside continued support from existing investors.

Insilico Medicine recently announced the closing of a $110 million Series E financing round, led by Value Partners, a Hong Kong-based firm, with participation from existing and new investors. The funds will be used to refine the company's AI models and support pivotal clinical trials for its lead candidate drug in idiopathic pulmonary fibrosis. The company's small molecule inhibitor, ISM001-055, was recently officially named rentosertib by the U.S. Adopted Names Council, marking a significant milestone for this AI-generated drug candidate.